JP2006508983A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006508983A5 JP2006508983A5 JP2004553785A JP2004553785A JP2006508983A5 JP 2006508983 A5 JP2006508983 A5 JP 2006508983A5 JP 2004553785 A JP2004553785 A JP 2004553785A JP 2004553785 A JP2004553785 A JP 2004553785A JP 2006508983 A5 JP2006508983 A5 JP 2006508983A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- carrier
- magnesium stearate
- thalidomide
- single dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002552 dosage form Substances 0.000 claims 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 10
- 235000019359 magnesium stearate Nutrition 0.000 claims 5
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 3
- 239000002775 capsule Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 229960003433 thalidomide Drugs 0.000 claims 3
- 229920002261 Corn starch Polymers 0.000 claims 2
- 239000008120 corn starch Substances 0.000 claims 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42601602P | 2002-11-14 | 2002-11-14 | |
| US60/426,016 | 2002-11-14 | ||
| PCT/US2003/036620 WO2004045579A2 (en) | 2002-11-14 | 2003-11-13 | Pharmaceutical compositions and dosage forms of thalidomide |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009119084A Division JP4927905B2 (ja) | 2002-11-14 | 2009-05-15 | サリドマイドの医薬組成物および剤形 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006508983A JP2006508983A (ja) | 2006-03-16 |
| JP2006508983A5 true JP2006508983A5 (enExample) | 2006-04-27 |
| JP5269280B2 JP5269280B2 (ja) | 2013-08-21 |
Family
ID=32326306
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004553785A Expired - Lifetime JP5269280B2 (ja) | 2002-11-14 | 2003-11-13 | サリドマイドの医薬組成物および剤形 |
| JP2009119084A Expired - Fee Related JP4927905B2 (ja) | 2002-11-14 | 2009-05-15 | サリドマイドの医薬組成物および剤形 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009119084A Expired - Fee Related JP4927905B2 (ja) | 2002-11-14 | 2009-05-15 | サリドマイドの医薬組成物および剤形 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7230012B2 (enExample) |
| EP (2) | EP2277512A3 (enExample) |
| JP (2) | JP5269280B2 (enExample) |
| KR (1) | KR100671366B1 (enExample) |
| CN (2) | CN101816626A (enExample) |
| AU (2) | AU2003290982C1 (enExample) |
| BR (1) | BR0316240A (enExample) |
| CA (1) | CA2505964C (enExample) |
| DK (1) | DK1562556T3 (enExample) |
| ES (1) | ES2403142T3 (enExample) |
| IL (1) | IL168585A (enExample) |
| MX (1) | MXPA05005162A (enExample) |
| NZ (1) | NZ540545A (enExample) |
| PT (1) | PT1562556E (enExample) |
| SI (1) | SI1562556T1 (enExample) |
| TW (2) | TWI377062B (enExample) |
| WO (1) | WO2004045579A2 (enExample) |
| ZA (1) | ZA200503927B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7230012B2 (en) * | 2002-11-14 | 2007-06-12 | Celgene Corporation | Pharmaceutical compositions and dosage forms of thalidomide |
| US7838029B1 (en) | 2003-07-31 | 2010-11-23 | Watson Laboratories, Inc. | Mirtazapine solid dosage forms |
| US7390503B1 (en) | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
| US20100009929A1 (en) | 2004-03-29 | 2010-01-14 | Cheng Jin Q | Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof |
| US20100028339A1 (en) | 2004-03-29 | 2010-02-04 | Cheng Jin Q | Compositions including triciribine and trastuzumab and methods of use thereof |
| WO2005094322A2 (en) | 2004-03-29 | 2005-10-13 | University Of South Florida | Effective treatment of tumors and cancer with triciribine and related compounds |
| US20110008327A1 (en) * | 2004-03-29 | 2011-01-13 | Cheng Jin Q | Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof |
| US20100173864A1 (en) * | 2004-03-29 | 2010-07-08 | Cheng Jin Q | Compositions including triciribine and one or more platinum compounds and methods of use thereof |
| US20100009928A1 (en) | 2004-03-29 | 2010-01-14 | Cheng Jin Q | Compositions including triciribine and taxanes and methods of use thereof |
| US7534381B2 (en) * | 2005-09-14 | 2009-05-19 | Isp Investments Inc. | Process and apparatus for forming agglomerates of a powder composition of an active and binder |
| CN1870631B (zh) * | 2005-11-11 | 2010-04-14 | 华为技术有限公司 | 媒体网关的门控方法 |
| KR101462693B1 (ko) * | 2006-08-16 | 2014-11-17 | 노파르티스 아게 | 고도 결정질 치료용 화합물의 고체 분산체 제조 방법 |
| ATE546133T1 (de) * | 2006-11-10 | 2012-03-15 | Alphaptose Gmbh | Orale dosierform mit trisubstituierten glycerin- verbindungen |
| US20090137631A1 (en) * | 2007-11-22 | 2009-05-28 | National Yang-Ming University | Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression |
| DK2391355T3 (en) | 2009-05-19 | 2017-02-27 | Celgene Corp | FORMULATIONS OF 4-AMINO-2- (2,6-DIOXOPIPERIDIN-3-YL) ISOINDOLIN-1,3-DION |
| KR101369936B1 (ko) * | 2011-12-28 | 2014-03-06 | 연세대학교 산학협력단 | 탈리도마이드를 포함하는 루프스 신염 치료용 약학 조성물 |
| JP5087182B1 (ja) | 2012-06-13 | 2012-11-28 | クリニプロ株式会社 | 吸入用パウダーの製造方法 |
| AU2015210999A1 (en) | 2014-01-29 | 2016-07-21 | Otsuka Pharmaceutical Co., Ltd. | Device-based risk management of a therapeutic |
| CN106137986B (zh) * | 2015-03-09 | 2019-04-16 | 常州制药厂有限公司 | 一种沙利度胺片及其制备方法 |
| CN106138052B (zh) * | 2015-04-16 | 2020-02-21 | 欣凯医药化工中间体（上海）有限公司 | 一种沙利度胺制剂及其制备方法 |
| CN111107874A (zh) | 2017-09-14 | 2020-05-05 | 葛兰素史密斯克莱知识产权发展有限公司 | 用于癌症的组合治疗 |
| CN111372585A (zh) | 2017-11-16 | 2020-07-03 | C4医药公司 | 用于靶蛋白降解的降解剂和降解决定子 |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| KR20210018199A (ko) | 2018-03-26 | 2021-02-17 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스의 분해를 위한 세레블론 결합제 |
| WO2019204354A1 (en) | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Spirocyclic compounds |
| EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
| EP3846800A4 (en) | 2018-09-04 | 2022-08-24 | C4 Therapeutics, Inc. | Compounds for the degradation of brd9 or mth1 |
| KR102735378B1 (ko) | 2018-11-09 | 2024-11-27 | 한국화학연구원 | 신규한 피페리딘-2,6-디온 유도체 및 이의 용도 |
| CN120698985A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| EP4470618A3 (en) | 2019-03-06 | 2025-03-05 | C4 Therapeutics, Inc. | Heterocyclic compounds for medical treatment |
| KR20210152515A (ko) | 2019-04-12 | 2021-12-15 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
| KR20220103952A (ko) | 2019-10-21 | 2022-07-25 | 셀진 코포레이션 | (s)-2-(2,6-디옥소피페리딘-3-일)-4-((2-플루오로-4-((3-모르폴리노아제티딘-1-일)메틸)벤질)아미노)이소인돌린-1,3-디온을 포함하는 제약 조성물 및 그의 사용 방법 |
| JP2023538517A (ja) | 2020-08-05 | 2023-09-08 | シーフォー セラピューティクス， インコーポレイテッド | Ｒｅｔの標的分解のための化合物 |
| EP4431505A4 (en) | 2021-11-09 | 2025-09-24 | Korea Res Inst Chemical Tech | ISOINDOLINONE DERIVATIVE HAVING A GLUTARIMIDE MOTHER NUCLEUS AND ITS USE |
| KR102823538B1 (ko) | 2021-11-09 | 2025-06-23 | 한국화학연구원 | 글루타이미드 모핵을 갖는 이소인돌리논 유도체 및 이의 용도 |
| KR20240066906A (ko) | 2022-11-08 | 2024-05-16 | 주식회사 온코드바이오 | 퀴놀린 아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도 |
| KR20240066904A (ko) | 2022-11-08 | 2024-05-16 | 주식회사 온코드바이오 | 아릴시클로알킬아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992014455A1 (en) | 1991-02-14 | 1992-09-03 | The Rockefeller University | METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES |
| US6114355A (en) | 1993-03-01 | 2000-09-05 | D'amato; Robert | Methods and compositions for inhibition of angiogenesis |
| US6228879B1 (en) | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
| US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US5405855A (en) | 1993-12-23 | 1995-04-11 | Andrulis Pharmaceuticals Corp. | Treatment of insulin resistant diabetes with thalidomine |
| US5434170A (en) | 1993-12-23 | 1995-07-18 | Andrulis Pharmaceuticals Corp. | Method for treating neurocognitive disorders |
| US6001828A (en) | 1995-06-05 | 1999-12-14 | Andrulis, Jr.; Peter | Use of tumor factor inhibitors together with antiviral agents and therapeutic compositions thereof against HIV infection |
| US5643915A (en) * | 1995-06-06 | 1997-07-01 | Andrulis Pharmaceuticals Corp. | Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies |
| US5731325A (en) | 1995-06-06 | 1998-03-24 | Andrulis Pharmaceuticals Corp. | Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents |
| US5654312A (en) | 1995-06-07 | 1997-08-05 | Andrulis Pharmaceuticals | Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents |
| WO1998019649A2 (en) | 1996-11-05 | 1998-05-14 | The Children's Medical Center Corporation | Methods and compositions for inhibition of angiogenesis |
| CA2319872C (en) * | 2000-02-02 | 2012-06-19 | Chun-Ying Huang | Pharmaceutical composition for the treatment of hepatocellular carcinoma |
| US20020022627A1 (en) * | 2000-03-31 | 2002-02-21 | Dannenberg Andrew J. | Inhibition of cyclooxygenase-2activity |
| JP4679028B2 (ja) * | 2000-05-15 | 2011-04-27 | セルジーン コーポレイション | 結腸直腸癌を治療するための組成物および方法 |
| WO2003080048A1 (en) * | 2002-03-20 | 2003-10-02 | Celgene Corporation | (-)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| US7230012B2 (en) * | 2002-11-14 | 2007-06-12 | Celgene Corporation | Pharmaceutical compositions and dosage forms of thalidomide |
-
2003
- 2003-06-30 US US10/608,077 patent/US7230012B2/en not_active Expired - Lifetime
- 2003-11-13 KR KR1020057008631A patent/KR100671366B1/ko not_active Expired - Fee Related
- 2003-11-13 CN CN201010115035A patent/CN101816626A/zh active Pending
- 2003-11-13 JP JP2004553785A patent/JP5269280B2/ja not_active Expired - Lifetime
- 2003-11-13 CA CA002505964A patent/CA2505964C/en not_active Expired - Lifetime
- 2003-11-13 CN CN200380108803.9A patent/CN1738607B/zh not_active Expired - Fee Related
- 2003-11-13 BR BR0316240-0A patent/BR0316240A/pt not_active IP Right Cessation
- 2003-11-13 DK DK03783567.5T patent/DK1562556T3/da active
- 2003-11-13 AU AU2003290982A patent/AU2003290982C1/en not_active Expired
- 2003-11-13 EP EP10175930A patent/EP2277512A3/en not_active Withdrawn
- 2003-11-13 PT PT37835675T patent/PT1562556E/pt unknown
- 2003-11-13 SI SI200332255T patent/SI1562556T1/sl unknown
- 2003-11-13 ES ES03783567T patent/ES2403142T3/es not_active Expired - Lifetime
- 2003-11-13 NZ NZ540545A patent/NZ540545A/en not_active IP Right Cessation
- 2003-11-13 MX MXPA05005162A patent/MXPA05005162A/es active IP Right Grant
- 2003-11-13 EP EP03783567A patent/EP1562556B1/en not_active Expired - Lifetime
- 2003-11-13 WO PCT/US2003/036620 patent/WO2004045579A2/en not_active Ceased
- 2003-11-14 TW TW096113473A patent/TWI377062B/zh not_active IP Right Cessation
- 2003-11-14 TW TW092132008A patent/TWI359659B/zh not_active IP Right Cessation
-
2005
- 2005-05-15 IL IL168585A patent/IL168585A/en active IP Right Grant
- 2005-05-16 ZA ZA200503927A patent/ZA200503927B/en unknown
-
2009
- 2009-05-15 JP JP2009119084A patent/JP4927905B2/ja not_active Expired - Fee Related
-
2010
- 2010-05-13 AU AU2010201931A patent/AU2010201931A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006508983A5 (enExample) | ||
| IL150568A0 (en) | A controlled release oral drug dosage form | |
| NZ590291A (en) | Pharmaceutical compositions for treatment of parkinson's disease | |
| CL2008000823A1 (es) | Formulacion farmaceutica de liberacion inmediata que comprende dapagliflozina propilenglicol hidrato y un portador farmaceuticamente aceptable; uso para tratar diabetes, intolerancia a la glucosa, resistencia a la insulina, entre otras. | |
| EP1435240A3 (en) | Solid oral dosage form comprising a combination of methformin and glibenclamide | |
| JP2003520232A5 (enExample) | ||
| JP2004155791A5 (enExample) | ||
| DE60238756D1 (de) | Opioid enthaltende arzneiform gegen missbrauch | |
| EA200801926A1 (ru) | Таблетки парацетамола с быстрым высвобождением | |
| JP2012031147A5 (enExample) | ||
| JP2012533559A5 (enExample) | ||
| JP2008516004A5 (enExample) | ||
| HRP20100120T1 (hr) | Formulacije s valsartanom | |
| JP2008515980A5 (enExample) | ||
| JP2019504848A5 (enExample) | ||
| ES2172481A1 (es) | Composicion farmaceutica que contiene citalopram. | |
| JP2007063263A5 (enExample) | ||
| MY139086A (en) | Use of debranched starch in extrusion-spheronization pharmaceutical pellets | |
| JP2019517536A5 (enExample) | ||
| CN201257161Y (zh) | 复方单硝酸异山梨酯双释胶囊 | |
| JP2006342148A5 (enExample) | ||
| JP2002538207A5 (enExample) | ||
| JP2008503445A5 (enExample) | ||
| MXPA06000363A (es) | Forma de dosificacion oral de mesilato de saquinavir. | |
| PT1858494E (pt) | Nova cápsula de gelatina mole |